Literature DB >> 21254143

Application of a novel boronated porphyrin (H₂OCP) as a dual sensitizer for both PDT and BNCT.

Ryo Hiramatsu1, Shinji Kawabata, Shin-Ichi Miyatake, Toshihiko Kuroiwa, Michael W Easson, M Graça H Vicente.   

Abstract

BACKGROUND AND
OBJECTIVE: Boronated porphyrins have emerged as promising dual sensitizers for use in both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT), by virtue of their known tumor affinity, low cytotoxicity in dark conditions, and easy synthesis with high boron content. Octa-anionic 5,10,15,20-tetra[3,5-(nido-carboranylmethyl)phenyl] porphyrin (H₂OCP) is a boronated porphyrin having eight boron clusters linked to the porphyrin ring. To evaluate H₂OCP's applicability to both PDT and BNCT, we performed an in vitro and ex vivo study using F98 rat glioma cells.
MATERIALS AND METHODS: We examined the time-dependent cellular uptake of H₂OCP by measuring the boron concentration over time, and compared the cellular uptake/clearance of boron after exposure to H₂OCP in conjunction with boronophenylalanine (BPA) and sodium borocaptate (BSH), both of which are currently used in clinical BNCT studies. We evaluated the cytotoxicity of H₂OCP-mediated PDT using a colony-forming assay and assessed the tumorigenicity of the implantation of pre-treated cells using Kaplan-Meier survival curves. Fluorescence microscopy was also performed to evaluate the cellular uptake of H₂OCP.
RESULTS: H₂OCP accumulated within cells to a greater extent than BPA/BSH, and H₂OCP was retained inside the cells to approximately the same extent as BSH. The cell-surviving fraction following laser irradiation (8 J/cm², 18 hours after exposure to 10 µg B/ml H₂OCP) was <0.05. The median survival times of the pre-treated cell-implanted rats were longer than those of the untreated group (P < 0.05). The fluorescence of H₂OCP was clearly demonstrated within the tumor cells by fluorescence microscopy.
CONCLUSIONS: H₂OCP has been proven to be a promising photosensitizer for PDT. H₂OCP has also been proposed as a potentially effective replacement of BPA or BSH, or as a replacement of both BPA/BSH. Our study provides more evidence that H₂OCP could be an effective novel dual sensitizing agent for use in both PDT and BNCT.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21254143      PMCID: PMC3164306          DOI: 10.1002/lsm.21026

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  22 in total

Review 1.  Photodynamic therapy for intracranial neoplasms. Literature review and institutional experience.

Authors:  T C Origitano; M J Caron; O H Reichman
Journal:  Mol Chem Neuropathol       Date:  1994 Feb-Apr

2.  Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds.

Authors:  A H Soloway; H Hatanaka; M A Davis
Journal:  J Med Chem       Date:  1967-07       Impact factor: 7.446

3.  Boron neutron capture therapy for newly diagnosed glioblastoma.

Authors:  Shinji Kawabata; Shin-Ichi Miyatake; Toshihiko Kuroiwa; Kunio Yokoyama; Atsushi Doi; Kyoko Iida; Shiro Miyata; Naosuke Nonoguchi; Hiroyuki Michiue; Masatsugu Takahashi; Taisuke Inomata; Yoshio Imahori; Mitsunori Kirihata; Yoshinori Sakurai; Akira Maruhashi; Hiroaki Kumada; Koji Ono
Journal:  J Radiat Res       Date:  2008-10-29       Impact factor: 2.724

4.  Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Kunio Yokoyama; Toshihiko Kuroiwa; Hiroyuki Michiue; Yoshinori Sakurai; Hiroaki Kumada; Minoru Suzuki; Akira Maruhashi; Mitsunori Kirihata; Koji Ono
Journal:  J Neurooncol       Date:  2008-09-24       Impact factor: 4.130

5.  Cure of Fisher rats bearing radioresistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-rays.

Authors:  Marie-Claude Biston; Aurélie Joubert; Jean-François Adam; Hélène Elleaume; Sylvain Bohic; Anne-Marie Charvet; François Estève; Nicolas Foray; Jacques Balosso
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

6.  Comparison of measured parameters from a 24-keV and a broad spectrum epithermal neutron beam for neutron capture therapy: an identification of consequential parameters.

Authors:  R G Fairchild; S K Saraf; J Kalef-Ezra; B H Laster
Journal:  Med Phys       Date:  1990 Nov-Dec       Impact factor: 4.071

7.  Synthesis of copper octabromotetracarboranylphenylporphyrin for boron neutron capture therapy and its toxicity and biodistribution in tumour-bearing mice.

Authors:  M Miura; G M Morris; P L Micca; M M Nawrocky; M S Makar; S P Cook; D N Slatkin
Journal:  Br J Radiol       Date:  2004-07       Impact factor: 3.039

8.  Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex.

Authors:  J A Coderre; T M Button; P L Micca; C D Fisher; M M Nawrocky; H B Liu
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-10-15       Impact factor: 7.038

Review 9.  Boron neutron capture therapy for cancer. Realities and prospects.

Authors:  R F Barth; A H Soloway; R G Fairchild; R M Brugger
Journal:  Cancer       Date:  1992-12-15       Impact factor: 6.860

10.  An improved rat brain-tumor model.

Authors:  N Kobayashi; N Allen; N R Clendenon; L W Ko
Journal:  J Neurosurg       Date:  1980-12       Impact factor: 5.115

View more
  6 in total

1.  Folate receptor-targeted novel boron compound for boron neutron capture therapy on F98 glioma-bearing rats.

Authors:  Takuya Kanemitsu; Shinji Kawabata; Masao Fukumura; Gen Futamura; Ryo Hiramatsu; Naosuke Nonoguchi; Fumiko Nakagawa; Takushi Takata; Hiroki Tanaka; Minoru Suzuki; Shin-Ichiro Masunaga; Koji Ono; Shin-Ichi Miyatake; Hiroyuki Nakamura; Toshihiko Kuroiwa
Journal:  Radiat Environ Biophys       Date:  2018-11-24       Impact factor: 1.925

2.  Pharmacokinetics of Chlorin e₆-Cobalt Bis(Dicarbollide) Conjugate in Balb/c Mice with Engrafted Carcinoma.

Authors:  Arthur B Volovetsky; Vladimir S Sukhov; Irina V Balalaeva; Varvara V Dudenkova; Natalia Yu Shilyagina; Аlexey V Feofanov; Anastasija V Efremenko; Mikhail A Grin; Andrey F Mironov; Igor B Sivaev; Vladimir I Bregadze; Anna V Maslennikova
Journal:  Int J Mol Sci       Date:  2017-11-28       Impact factor: 5.923

3.  Synthesis and Evaluation of Dodecaboranethiol Containing Kojic Acid (KA-BSH) as a Novel Agent for Boron Neutron Capture Therapy.

Authors:  Koji Takeuchi; Yoshihide Hattori; Shinji Kawabata; Gen Futamura; Ryo Hiramatsu; Masahiko Wanibuchi; Hiroki Tanaka; Shin-Ichiro Masunaga; Koji Ono; Shin-Ichi Miyatake; Mitsunori Kirihata
Journal:  Cells       Date:  2020-06-25       Impact factor: 6.600

Review 4.  Carboranes as unique pharmacophores in antitumor medicinal chemistry.

Authors:  Yu Chen; Fukuan Du; Liyao Tang; Jinrun Xu; Yueshui Zhao; Xu Wu; Mingxing Li; Jing Shen; Qinglian Wen; Chi Hin Cho; Zhangang Xiao
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

5.  Synthesis of meso-substituted dihydro-1,3-oxazinoporphyrins.

Authors:  Satyasheel Sharma; Mahendra Nath
Journal:  Beilstein J Org Chem       Date:  2013-03-07       Impact factor: 2.883

Review 6.  Boron Neutron Capture Therapy for Malignant Brain Tumors.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Ryo Hiramatsu; Toshihiko Kuroiwa; Minoru Suzuki; Natsuko Kondo; Koji Ono
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-05-31       Impact factor: 1.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.